RCAN1-4 is a thyroid cancer growth and metastasis suppressor
Authors:
- Chaojie WangCWChaojie Wang
- Motoyasu SajiMSMotoyasu Saji
- Steven E. JustinianoSJSteven E. Justiniano
- Adlina Mohd YusofAYAdlina Mohd Yusof
- Xiaoli ZhangXiaoli Zhang
- Lianbo YuLYLianbo Yu
- Krista La PerleKPKrista La Perle
- Hiroshi NakanishiHNHiroshi Nakanishi
- Neal PohlmanNPNeal Pohlman
- Matthew D. RingelMRMatthew D. Ringel
Open Access
- 9 March 2017
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (5) , e90651
Abstract
Metastasis suppressors are key regulators of tumor growth, invasion, and metastases. Loss of metastasis suppressors has been associated with aggressive tumor behaviors and metastatic progression. We previously showed that regulator of calcineurin 1, isoform 4 (RCAN1-4) was upregulated by the KiSS1 metastatic suppression pathway and could inhibit cell motility when overexpressed in cancer cells. To test the effects of endogenous RCAN1-4 loss on thyroid cancer in vivo, we developed RCAN1-4 knockdown stable cells. Subcutaneous xenograft models demonstrated that RCAN1-4 knockdown promotes tumor growth. Intravenous metastasis models demonstrated that RCAN1-4 loss promotes tumor metastases to the lungs and their subsequent growth. Finally, stable induction of RCAN1-4 expression reduced thyroid cancer cell growth and invasion. Microarray analysis predicted that nuclear factor, erythroid 2-like 3 (NFE2L3) was a pivotal downstream effector of RCAN1-4. NFE2L3 overexpression was shown to be necessary for RCAN1-4–mediated enhanced growth and invasiveness and NEF2L3 overexpression independently increased cell invasion. In human samples, NFE2L3 was overexpressed in TCGA thyroid cancer samples versus normal tissues and NFE2L3 overexpression was demonstrated in distant metastasis samples from thyroid cancer patients. In conclusion, we provide the first evidence to our knowledge that RCAN1-4 is a growth and metastasis suppressor in vivo and that it functions in part through NFE2L3.Keywords
This publication has 57 references indexed in Scilit:
- Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancerOncogene, 2011
- Metastatic Dormancy and Progression in Thyroid Cancer: Targeting Cells in the Metastatic FrontierThyroid®, 2011
- NFAT proteins: emerging roles in cancer progressionNature Reviews Cancer, 2009
- The Down syndrome critical region gene 1 short variant promoters direct vascular bed–specific gene expression during inflammation in miceJournal of Clinical Investigation, 2009
- Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1Nature, 2009
- The RCAN carboxyl end mediates calcineurin docking-dependent inhibition via a site that dictates binding to substrates and regulatorsProceedings of the National Academy of Sciences, 2009
- Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and MisidentificationThe Journal of Clinical Endocrinology & Metabolism, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Tumor‐vascular interactions and tumor dormancyAPMIS, 2008
- Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical ApplicationClinical Cancer Research, 2006